Aberrant expression of pRb, p16, p14ARF, MDM2, p21 and p53 in stage I adenocarcinomas of the lung

被引:20
作者
Xue, Q [1 ]
Sano, T [1 ]
Kashiwabara, K [1 ]
Saito, M [1 ]
Oyama, T [1 ]
Nakajima, T [1 ]
机构
[1] Gunma Univ, Sch Med, Dept Pathol 2, Maebashi, Gumma 3718511, Japan
关键词
adenocarcinoma; immunohistochemistry; lung; p53; pathway; pRb pathway;
D O I
10.1046/j.1440-1827.2002.01321.x
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Cancers are always associated with cell cycle abnormalities. To clarify the cell cycle abnormalities present in lung adenocarcinomas, various cell cycle regulatory proteins of both the pRb and p53 pathways were studied immunohistochemically in 50 cases of stage I adenocarcinoma of the lung. In regard to the pRb pathway, most adenocarcinomas showed frequent expression of both p16 and pRb proteins, and aberrant expression in the pRb pathway was observed in about one-quarter of stage I adenocarcinomas. In regard to the p53 pathway, the frequency of immunohistochemical positivity was 8% for p14ARF, 64% for MDM2, 20% for p53 and 24% for p21. In this pathway, the immunohistochemical profile of p14ARF-negative/MDM2-positive/p53-negative is characteristic of stage I adenocarcinoma of the lung. An inverse relationship was found between MDM2 and p53 protein and was associated with the differentiation status of stage I adenocarcinoma of the lung. Our results suggest that the disruption of the pRb and p53 pathways is frequently observed in the early stages of lung adenocarcinoma and might play an important role in the growth and differentiation of adenocarcinoma of the lung.
引用
收藏
页码:103 / 109
页数:7
相关论文
共 50 条
[1]   MDM2 EXPRESSION IS INDUCED BY WILD TYPE-P53 ACTIVITY [J].
BARAK, Y ;
JUVEN, T ;
HAFFNER, R ;
OREN, M .
EMBO JOURNAL, 1993, 12 (02) :461-468
[2]   Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas [J].
Burns, KL ;
Ueki, K ;
Jhung, SL ;
Koh, J ;
Louis, DN .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1998, 57 (02) :122-130
[3]   p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells [J].
Chen, XB ;
Ko, LJ ;
Jayaraman, L ;
Prives, C .
GENES & DEVELOPMENT, 1996, 10 (19) :2438-2451
[4]   The INK4a/ARF tumor suppressor: one gene - two products - two pathways [J].
Chin, L ;
Pomerantz, J ;
DePinho, RA .
TRENDS IN BIOCHEMICAL SCIENCES, 1998, 23 (08) :291-296
[5]  
Esteller M, 2000, CANCER RES, V60, P129
[6]   K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer [J].
Fukuyama, Y ;
Mitsudomi, T ;
Sugio, K ;
Ishida, T ;
Akazawa, K ;
Sugimachi, K .
BRITISH JOURNAL OF CANCER, 1997, 75 (08) :1125-1130
[7]  
Geradts J, 1999, CLIN CANCER RES, V5, P791
[8]  
Gorgoulis VG, 1996, MODERN PATHOL, V9, P544
[9]   Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas - Relationship with p53 and MDM2 protein expression [J].
Gorgoulis, VG ;
Zacharatos, P ;
Kotsinas, A ;
Liloglou, T ;
Kyroudi, A ;
Veslemes, M ;
Rassidakis, A ;
Halazonetis, TD ;
Field, JK ;
Kittas, C .
AMERICAN JOURNAL OF PATHOLOGY, 1998, 153 (06) :1749-1765
[10]   Association between p53 mutation and clinicopathological features of non-small cell lung cancer [J].
Guang, SG ;
Ogura, T ;
Sekine, I ;
Yokozaki, M ;
Esumi, H ;
Kodama, T ;
Nagai, K .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1997, 27 (04) :211-215